Navigation Links
ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack

TUSTIN, Calif., May 20, 2010 -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine (PS)-targeting antibody bavituximab for the treatment of solid tumors. PS-targeting antibodies represent an entirely new approach to treating cancer, using a novel immunomodulatory mechanism that enables the patient's own immune system to attack and destroy the tumor. Phase II data on the company's lead PS-targeting antibody bavituximab administered in combination with chemotherapy will be presented at the 2010 ASCO Annual Meeting.

"PS is a highly immunosuppressive molecule that inactivates the immune system and allows tumors to evade detection," commented Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center, a scientific advisor to Peregrine and a pioneer in the development of PS-targeting therapies. "Supported by a growing body of research, PS-targeting antibodies appear to play a critical role in blocking this immunosuppressive molecule and reactivating the immune system's ability to mount a robust anti-tumor response. Since chemotherapy increases the exposure of PS on tumor blood vessels, bavituximab has even more of this immunosuppressive molecule to target, potentially offering a new synergistic approach for the treatment of cancer."

Based on the positive data reported to date, Peregrine plans to initiate a new randomized, placebo-controlled, double-blinded Phase II trial of bavituximab in combination with chemotherapy in refractory non-small cell lung cancer (NSCLC) patients. A new Phase II trial in front-line NSCLC patients is also expected to begin in by mid-year.

Reactivating the Immune System by Blocking "Flipped" Phospholipids

Usually located on the inside of healthy cell membranes, PS "flips" and becomes exposed on the outside of cells that line tumor blood vessels. PS also becomes exposed on virus-infected cells and enveloped viruses. A growing body of scientific evidence shows that this exposed PS inactivates the body's normal immune response.

The "flipped" PS molecules therefore create a specific target for anti-cancer and anti-viral treatments, leaving healthy cells unaffected. Peregrine's PS-targeting antibodies such as bavituximab target and block this immunosuppressive PS target, enabling the immune system to recognize the cancer cells as foreign and to reactivate the immune system to attack the tumor and inhibit its growth.

Clinical Evidence Synergistic Mechanism of Action

Clinical evidence supporting the PS-targeting approach will be discussed in three sessions at the 2010 ASCO Annual Meeting. Prior clinical data show that in combination with chemotherapy in advanced breast and lung cancer patients, Peregrine's first-in-class antibody bavituximab has achieved objective tumor response rates that compare favorably with chemotherapy alone. Bavituximab has also demonstrated a promising safety profile.

Of special interest, these prior clinical data also suggest that the PS-targeting mechanism may have additive therapeutic effects with other cancer treatments. This builds on preclinical studies that have previously shown that a number of FDA-approved anti-cancer treatments up-regulate the PS exposed on the tumor vasculature. Numerous preclinical studies have also demonstrated enhanced anti-tumor effects of PS-targeting antibodies when used in combination with a range of standard anti-cancer treatments, including radiation, chemotherapy, hormone depletion therapy and most recently, agents that induce apoptosis.

ASCO posters reporting bavituximab Phase II clinical results include:

Saturday, June 5, 2010, 2:00 6:00 pm CT

Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer (Abstract #1042), Author: David Tabagari, Poster Board 22C, S Hall A2

Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results (Abstract #1062), Author: Minish Jain, Poster Board 22G, S Hall A2

Sunday, June 6, 2010, 8:00 12:00 pm CT

Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results (Abstract #7589), Author: Raghunadharao Digumarti, Poster Board 40H, S Hall A2


Contact: Barbara Lindheim
BioCom Partners

Related medicine news :

1. TCT for Surgeons course will highlight hybrid surgical and interventional techniques
2. Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010
3. Health: Stem Cell Breakthrough Highlights Adult Stem Cell Promise Says Christian Drapeau
4. St. Vincent's Hospital Layoffs Highlight Need for WARN Notice and Remedies
5. Professional Members of Human Rights Organization Hold Press Conference to Highlight Government Invasion of Privacy
6. CCH Briefing Highlights Employer, Medicare Provisions of Health Care Reform Proposals
7. Special Session Highlights Late-Breaking Abstracts
8. DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2009 Financial Results and Corporate Highlights Conference Call
9. Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns
10. FDA Cancer Drug Approval Rate Highlighted in JNCI
11. New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology: